Inhalation Sciences signs collaboration agreement with leading Indian multinational pharma company
Inhalation Sciences AB (ISAB) has signed a collaboration agreement with a leading Indian multinational pharma company with a powerful respiratory portfolio and a major presence in over 80 markets worldwide. The company has chosen DissolvIt[®],[ ]ISAB’s in vitro dissolution and absorption module, for its Inhalation Research project.
The company is ISAB’s first Indian client and is a highly agile, innovative multinational with a large number of development projects ongoing and a YoY R&D investment that has grown continuously over recent years. The Indian pharmaceutical industry as a whole is a major global exporter and one of the largest and fastest growing in the world. Recent increased investment in R&D and innovation from industry and government has been a significant factor in its growth.
In the present collaboration, the company has chosen to use ISAB’s research services to assess the dissolution properties of one of their inhalation drugs in their complex generics pipeline with the in vitro system DissolvIt®. DissolvIt® is an advanced dissolution method designed specifically for inhaled substances generating data that better correlate with the properties of the same drugs in clinical trials on patients, so potentially reducing risk and costs.
ISAB CEO Manoush Masarrat: “This is an exciting client that adds to our customer list of major pharmaceutical companies in the complex generics area. We are proud to have been chosen by such a prestigious and powerful presence in the global pharma field and look forward to further cooperation”.
Explore DissolvIt’s capabilities here.
Read ISAB’s publications on DissolvIt® here.
Explore Inhalation Research Services here
For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.firstname.lastname@example.org Mobile: +46 (0)73 628 9153Press release in PDF format